

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

## **1. Supplemental Methods**

### **Supplemental Method S1. Prioritization of candidate causal genes for eight identified genomic loci**

To further explore the causal effects of nine index SNPs in eight genomic loci on severe COVID-19, we performed a prioritization analysis by leveraging the Open Target Genetics (OTG, <https://genetics.opentargets.org/>) tool (1). The OTG tool is a web-access integrative resource that aggregates human GWAS summary statistics, including UK Biobank data and NHGRI-EBI GWAS catalog, and functional genomic data, including protein quantitative trait loci data (pQTLs), expression QTL (eQTL) from eQTL Catalogue, eQTLGen and GTEx, and promoter capture hiC (PCHI-C) from 27 different cell types, and DNase I hypersensitive site (DHS)-gene promoter correlation and other datasets from a wide range of cell types and tissues. Based on the Variant2Gene (V2G) algorithm, for the index SNP rs2166172 in 1p22.2, we prioritized *BARHL2* as a candidate causal gene for severe COVID-19. With the highest V2G score, *CCHCR1* was highlighted as candidate causal gene for the index SNP rs143334143 in 6p21.33, *VSTM2A* as candidate causal gene for rs622568 in 7p11.2, *OAS1* as candidate causal gene for rs2269899 in 12q24.13, *DPP9* as candidate causal gene for rs2109069 in 19p13.3, and *IFNAR2* as candidate causal gene for rs13050728 in 21q22.11. The index SNP of rs13050728 ( $P = 1.91 \times 10^{-11}$ ) in 21q22.11 is highly LD with the reported SNP of rs9976829 ( $R^2 = 1$ ) (2) and rs2236757 ( $R^2 = 0.8266$ ) (3). The index SNP of rs2269899 in 12q24.13 ( $P = 3.24 \times 10^{-8}$ ) shows high LD with the reported SNP of rs10735079 ( $R^2 = 0.9282$ ) (3).

### **Supplemental Method S2. Combination of GWAS summary statistics with scRNA-seq data (dataset #1) by using the MAGMA algorithm**

25 As an independent technical approach to validate genetics-related peripheral immune cells in  
26 PBMCs implicated in severe COVID-19 identified from the RolyPoly algorithm, we applied a  
27 generalized linear regression (GLR) model in the MAGMA (v1.06,  
28 <https://ctg.cncr.nl/software/magma>) (4). Conditioning on the 10% most specific genes from the  
29 single cell data for each cell type, we examined gene-level genetic associations of severe COVID-  
30 19-associated immune cell types by adding these variables as covariates for the linear regression  
31 model. The specificity of each gene for each cell type was calculated by using the mean gene  
32 expression of cell type divided the sum of mean gene expression across all cell types. A window  
33 of 50 kb upstream to 50 kb downstream for a given gene coordinates was set to calculate gene-  
34 level association statistics. The 1,000 Genome Project European Phase 3 panel (5) was used as the  
35 reference panel for both methods. We restricted the GLR analysis to SNPs in the autosomes, and  
36 any SNPs with minor allele frequency < 5% were excluded. The major histocompatibility  
37 complex region (Chr6: 25-35 Mbp) was also excluded due to the extensive linkage disequilibrium  
38 (LD) in this region.


39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50

51 **2. Supplemental Figures**

52

53 **Supplemental Figure S1. UMAP projections of cells in PBMCs from normal controls, mild,**  
54 **moderate, and severe COVID-19 patients by using the Seurat R package (dataset #1).** Dark  
55 green represents normal controls, light green represents mild patients, orange represents moderate  
56 patients, and red represents severe patients.



57

58

59

60

61

62

63


64

65

66

67

68 **Supplemental Figure S2. Heatmap showing levels of well-known marker genes specific for**  
69 **each cell type in PBMCs.** Color legend represents the expression level of each marker gene.



70

71

72

73

74

75

76

77

78

79

80


81

82

83

84

86 **Supplemental Figure S3. Single-cell transcriptomes of PBMCs from normal controls, mild,**  
 87 **moderate, and severe COVID-19 patients.** A) UMAP projections of 514,400 cells from normal  
 88 controls, mild, moderate, and severe patients colored by annotated cell types. There was 13  
 89 clusters with 13 distinct cell types annotated by using well-known markers. B) Normalized  
 90 expression of marker genes on a UMAP plot. For example, the well-known markers of CD14,  
 91 NKG7, PRF1, GNLY, GZMB, LEF1, CD4, CD8A, GZMK, FCGR3A, and NR4A1. C)  
 92 Proportion of cell types among normal controls, mild, moderate, and severe patients. D) Violin  
 93 plots of selected markers (lower row) for 13 cell subpopulations. The left column shows the cell  
 94 types annotated by combinations of markers.



95

96

97

98


99

100


101



119 **Supplemental Figure S5. Boxplots showing percentages of each cell type for PBMCs in**  
120 **donors from healthy control and COVID-19 patients with different severities based on the**  
121 **combined dataset. The statistical analysis for calculating difference among different groups was**  
122 **based on the Wilcoxon sum-rank test.**




125 **Supplemental Figure S6. Regional association plots for severe COVID-19-associated genetic**  
 126 **loci based on meta-GWAS summary data. A-F) 1p22.2, 6p21.33, 7p11.2, 12q24.13, 19p13.3**  
 127 **and 21q22.11. The purple diamond marks the most strongly associated SNP in each locus with**  
 128 **severe COVID-19. The color illustrates LD information with the given SNP, as shown in the**  
 129 **color legend. The detailed information is shown in Supplemental Table S3.**






134 **Supplemental Figure S7. Regional association plots for severe COVID-19-associated genetic**  
 135 **loci based on meta-GWAS summary data.** A-B) Two independent genetic association signals in  
 136 the 3p21.31 loci (rs35081325,  $P = 3.32 \times 10^{-58}$ , and rs33998492,  $P = 3.59 \times 10^{-14}$ , respectively). The  
 137 purple diamond marks the most strongly associated SNP in each locus with severe COVID-19.  
 138 The color illustrates LD information with the given SNP, as shown in the color legend. C) The  
 139 results of calculating the LD information between rs35081325 and rs33998492 using the LDpair  
 140 Tool based on the European population (EUR+TSI). D) Regional association plot for the 9q34.2  
 141 locus associated with severe COVID-19.




149 **Supplemental Figure S8. Circus plot showing the results of MAGMA-based gene-level**  
 150 **association analysis.** A for lung tissue, and B for blood. The inner ring demonstrates the 22  
 151 autosomal chromosomes (Chr1-22) and X chromosome. In the outer ring, a circular symbol stands  
 152 for a specific gene, and color marks the significant level of the gene. Red color marks genes  
 153 significantly associated with severe COVID-19 with  $FDR < 0.05$ , orange color indicates genes  
 154 suggestively associated with severe COVID-19 with  $6.96 \times 10^{-5} \leq P < 0.001$ , light blue color marks  
 155 suggestive genes with  $0.001 \leq P < 0.05$ , and dark blue indicates genes have non-significant  
 156 associations ( $P > 0.05$ ).  
 157




158  
 159  
 160  
 161  
 162  
 163  
 164  
 165

166 **Supplemental Figure S9. The 19 biological pathways enriched from the MAGMA-based**  
 167 **pathway enrichment analysis.** A) Barplot showing the 19 biological pathways based on the  
 168 KEGG pathway. B) Multidimensional scaling plot for clustering the 19 biological pathways based  
 169 on their Jaccard distance (see the Methods). Color represents gene number in each pathway, and  
 170 circular ring size indicates the Z score of enrichment for each pathway. The detailed information  
 171 is shown in Supplemental Table S5.  
 172




173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186

187 **Supplemental Figure S10. High consistence results between MAGMA and S-MultiXcan**  
 188 **analysis.** A) Venn diagram exhibiting the overlapped significant genes between MAGMA and S-  
 189 MultiXcan analysis. B) Correlation of significant risk genes identified from MAGMA and S-  
 190 MultiXcan analysis.  
 191




192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206

207 **Supplemental Figure S11. *In silico* permutation analysis of 100,000 times of random**  
208 **selections.** A) The comparison of the top-ranked genes from MAGMA gene-based analysis ( $P < 0.05$ )  
209 with that from S-MultiXcan-based analysis ( $P < 0.05$ ). B) The comparison of the top-ranked  
210 genes from MAGMA gene-based analysis ( $P < 0.05$ ) with that from S-PrediXcan-based analysis  
211 based on lung tissue ( $P < 0.05$ ). C) The comparison of the top-ranked genes from MAGMA gene-  
212 based analysis ( $P < 0.05$ ) with that from S-PrediXcan-based analysis based on blood tissue ( $P <$   
213  $0.05$ ).




214  
215  
216  
217  
218  
219

**Supplemental Figure S12. Multiple independent approaches identify genetics-relevant risk genes associated with severe COVID-19.** A) Venn diagram showing the overlapped genes among SNP-level association analysis, MAGMA gene-based analysis, S-MultiXcan analysis, and S-PrediXcan analysis based on lung and blood. B) Summary of total 34 genetically risk genes associated with severe COVID-19.



237 **Supplemental Figure S13. The 10 biological pathways significantly enriched by 34 risk**  
 238 **genes based on the KEGG database.** A) Barplot showing these 10 biological pathways  
 239 associated with severe COVID-19. The Arabic numeral in each bar represents the ID of each  
 240 pathway ordered by the significant level (Supplemental Table S10). B) Multidimensional scaling  
 241 plot for clustering these 10 pathways based on the Jaccard distance (see Methods). Color  
 242 represents the significance of each pathway (red color marks the significant pathways with lowest  
 243 P values).  
 244



245

246

247

248

249

250

251

252

253

254

255


256

257

258


259

260 **Supplemental Figure S14. Plot of gene-drug interaction analysis for 34 risk genes.** The gene-  
261 drug information was downloaded from the STITCH database (<http://stitch.embl.de/>). The orange  
262 node represents the risk gene, and the light green color stands for the targeted drugs. For more  
263 detail information, see the method for gene-drug interaction analysis.  
264






276 **Supplemental Figure S15. Genetics-risk genes influenced three immune cell subsets for**  
 277 **severe COVID-19.** A) Plot showing the specific genes expressed in three identified immune cell  
 278 subsets for severe COVID-19. The most specificity gene for each cell type is *CCR1* for  
 279 CD16+monocytes, *CXCR6* for memory CD8+T cells, and *ABO* for megakaryocytes. B) Dot plot  
 280 showing the expressed percent of three risk genes of *CXCR6*, *CCR1*, and *ABO* in each peripheral  
 281 cell type in PBMCs among severe patients based on the scRNA-seq dataset #1 (E-MTAB-9357).  
 282 Dot size represents fraction of cells within cell type expressing a given gene, and color intensity  
 283 represents binned count-based expression amounts (log(scaled UMI +1)) among expressing cells.



298 **Supplemental Figure S16. Dot plot showing the expressed percent of three risk genes of**  
 299 ***CXCR6*, *CCR1*, and *ABO* in each peripheral cell type in PBMCs among severe patients**  
 300 **based on two scRNA-seq dataset of #2 (GSE149689) and #3 (GSE150861).** Dot size represents  
 301 fraction of cells within cell type expressing a given gene, and color intensity represents binned  
 302 count-based expression amounts (log(scaled UMI +1)) among expressing cells.



303

304

305

306

307

308

309

310

311


312

313

314

315 **Supplemental Figure S17. *CCR1*<sup>+</sup> CD16+monocytes showing higher risk to cytokine storms**  
 316 **among COVID-19 patients. A) Boxplot showing the difference of pathway activity score of both**  
 317 **cytokine-cytokine receptor interaction and chemokine signaling pathway between *CCR1*<sup>+</sup> and**


318 *CCR1*<sup>-</sup> CD16<sup>+</sup> monocytes. Two-side Wilcoxon sum-rank test was used to calculate the  
 319 significance. B)-C) Barplot showing the proportion of significant druggable proteins (B) and  
 320 significant druggable proteins associated with COVID-19 (C) between *CCR1*<sup>+</sup> and *CCR1*<sup>-</sup>  
 321 CD16<sup>+</sup> monocytes. The hypergeometric test was applied to calculate the significance. D) Venn  
 322 plot exhibiting the overlapped up-DEGs between pairwise comparisons of mild vs. normal,  
 323 moderate vs. normal, and severe vs. normal. E) Functional enrichment analysis based on GO  
 324 biological process for 190 up-DEGs. F) Gene-drug interaction analysis for 190 up-DEGs. G)-L)  
 325 Representative up-DEGs among *CCR1*<sup>+</sup> CD16<sup>+</sup> monocytes showing significantly elevated  
 326 expressions with increased COVID-19 severities. G) *IRF3*, H) *CXCL8*, I) *CD14*, J) *S100A12*, K)  
 327 *IFI6*, and L) *IGSF6*.



328

329 **Supplemental Figure S18. *ABO*<sup>+</sup> megakaryocytes contribute higher risk to cytokine storms among**  
 330 **severe COVID-19 patients.** A)-B) Boxplot showing the difference of inflammatory cytokine score (A) and  
 331 pathway active score (B) between *ABO*<sup>+</sup> and *ABO*<sup>-</sup> megakaryocytes. There were two pathways of cytokine-cytokine

332 receptor interaction and chemokine signaling pathway used. Two-side Wilcoxon test was applied. C) Volcano plot  
 333 showing differentially expressed genes between *ABO*<sup>+</sup> and *ABO*<sup>-</sup> megakaryocytes. There were 424 highly-expressed  
 334 genes among *ABO*<sup>+</sup> megakaryocytes compared with *ABO*<sup>-</sup> cells. D) Pathway enrichment analysis of 424 highly-  
 335 expressed genes based on the KEGG resource. E) Barplot exhibiting the proportion of *ABO*<sup>+</sup> megakaryocytes among  
 336 normal controls, mild, moderate, and severe COVID-19 patients. F) Barplot showing the differentially up-DEGs from  
 337 the pairwise comparisons of normal controls with different COVID-19 severities. Venn plot on the top of bar  
 338 showing the overlapped up-DEGs between moderate and severe patients. G) Heatmap showing the up-DEGs from the  
 339 pairwise comparisons. F) Gene-drug interaction analysis for 35 up-DEGs. I-N) Representative up-DEGs among  
 340 *ABO*<sup>+</sup> megakaryocytes showing significantly elevated expressions with increased COVID-19 severities.




341

342


343 **Supplemental Figure S19. Evidence showing the multi-functionality of *CXCR6*<sup>+</sup> memory CD8<sup>+</sup>T**  
 344 **cells for severe COVID-19. A)-C) Boxplots showing the difference of inflammatory score (A),**  
 345 **proliferation score (B), and migration score (C) between *CXCR6*<sup>+</sup> and *CXCR6*<sup>-</sup> memory CD8<sup>+</sup>T cells.**

346 Two-side Wilcoxon sum-rank test was used. D) Pathway enrichment analysis of 158 highly-expressed  
 347 genes based on the KEGG resource. E)-F) Boxplots showing the cytotoxicity score (E) and exhaustion  
 348 score (F) of among normal, mild, moderate, and severe groups. G)-N) Representative up-DEGs among  
 349 *CXCR6*<sup>+</sup> memory CD8+T cells showing significantly elevated expressions with increased COVID-19  
 350 severities. G) *TCF7*, H) *HELB*, I) *COPS6*, J) *PSMB6*, K) *PUF60*, L) *RAB51F*, M) *NDUFAF3*, and N)  
 351 *HLA-DPB1*.



352  
 353  
 354  
 355  
 356  
 357  
 358 **Supplemental Figure S20. Differences in the number of predicated cell-to-cell interactions in**  
 359 **PBMCs, comparing severe COVID-19 patients with normal controls. Color legend represents**


360 the differential number of cellular interactions. Red rectangle marks the elevated interactions of  
 361 both *CCR1*<sup>+</sup> CD16<sup>+</sup> monocytes and *CXCR6*<sup>+</sup> memory CD8<sup>+</sup>T cells with other immune cells in  
 362 PBMCs.



363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374

375 **Supplemental Figure S21. Prediction of cell-to-cell interactions of cells in BALFs.** A) The  
 376 number of predicated cellular interactions of cells in BALFs. Color legend represents the number  
 377 of predicted cellular interactions. The Arabic numerals in the heatmap represent the specific

378 number of cellular interactions between pairwise cell types in BALFs. B) The increased percent  
 379 of cellular interactions of *CCR1*<sup>+</sup> CD16+ monocytes with epithelial cells compared with *CCR1*<sup>-</sup>  
 380 CD16+ monocytes. C) The increased percent of cellular interactions of *CXCR6*<sup>+</sup> memory CD8+T  
 381 cells with epithelial cells compared with *CXCR6*<sup>-</sup> memory CD8+T cells.  
 382



383  
384  
385  
386  
387  
388  
389  
390  
391

392 **3. Supplemental Tables**

393 **Supplemental Table S1. Samples collected from four independent scRNA-seq datasets on**  
 394 **COVID-19**

Characteristics	Dataset #1 (E-MTAB-9357)	Dataset #2 (GSE149689)	Dataset #3 (GSE150861)	Dataset #4 (GSE158055)	Total samples
Normal controls	16	4	0	0	20
Mild COVID-19	96	5	0	0	101
Moderate COVID-19	106	0	0	3	109
Severe COVID-19	52	6	3	9	70
Remission	0	0	4	0	4

395  
 396 **Supplemental Table S2. Selected well-known markers used to define cell types in PBMCs**

Cell types	Markers
CD14+ monocytes	<i>CD14, CD4, NR4A1</i>
CD16+ monocytes	<i>FCGR3A, CX3CR1, CD16, CD4, NR4A1</i>
Naïve CD4+T cells	<i>LEF1, CD197, TCF7, CD3D, CD3E, CD4</i>
Naïve CD8+T cells	<i>LEF1, CD197, TCF7, CD3D, CD3E, CD8A</i>
Effector CD4+T cells	<i>PRDM1, PRF1, GZMB, GNLY, CD3D, CD3E, CD4</i>
Effector CD8+T cells	<i>PRDM1, PRF1, GZMB, GNLY, CD3D, CD3E, CD8A</i>
Memory CD4+T cells	<i>GZMK, CD69, AQP3, CD3D, CD3E, CD4</i>
Memory CD8+T cells	<i>GZMK, CD69, AQP3, CD3D, CD3E, CD8A</i>
Exhaustion CD4+T cells	<i>LAG3, TIGIT, CD279, PDCD1, TIM3, CD3D, CD3E, CD4</i>
Exhaustion CD8+T cells	<i>LAG3, TIGIT, CD279, PDCD1, TIM3, CD3D, CD3E, CD8A</i>
Proliferating CD4+T cells	<i>MK167, TYMS, CD3D, CD3E, CD4</i>
Proliferating CD8+T cells	<i>MK167, TYMS, CD3D, CD3E, CD8A</i>
Regulatory CD4+T cells	<i>FOXP3, CD3D, CD3E, CD4</i>
Regulatory CD8+T cells	<i>FOXP3, CD3D, CD3E, CD8A</i>
NK	<i>FCGR3A, CD16, TRGC1, NKG7, NCAM1, CD38, CD62L, GZMB, CD56</i>
B	<i>CD79A, MS4A1, CD19</i>
Plasma B	<i>CD79A, CD38</i>
Naïve B	<i>IGHD, FCER2</i>
mDC	<i>CD14, CD1C</i>
pDC	<i>CLEC4A, CD123</i>
Megakaryocyte	<i>PPBP</i>
Progenitor	<i>CD34, CD38</i>
DC	<i>FCERIA, IL3RA, CD1C, CD141</i>

397  
 398 **Supplemental Table S3. Significant SNPs associated with severe COVID-19 identified by**  
 399 **meta-GWAS analysis**



SNP	CHR	POS	Loci	ATL	OR (95% CI)	Meta P-value
rs35081325	3	45489921	3p21.31	T	1.81 (1.788-1.853)	3.32E-58
rs2109069	19	4319443	19p13.3	A	1.183 (1.175-1.191)	6.40E-13
rs13050728	21	34215210	21q22.11	C	0.858 (0.851-0.865)	1.914E-11
rs143334143	6	30721426	6p21.33	A	1.273 (1.241-1.273)	1.283E-10
rs505922	9	135749229	9q34.2	T	0.88 (0.875-0.886)	2.24E-09
rs622568	7	54247894	7p11.2	C	1.167 (1.158-1.175)	2.57E-08
rs2166172	1	90808514	1p22.2	C	1.132 (1.126-1.137)	2.74E-08
rs2269899	12	112981956	12q24.13	T	1.132 (1.127-1.138)	3.24E-08

**Note:** SNP =single nucleotide polymorphism, CHR = chromosome, POS = position, ATL = altered allele, OR = odds ratio, 95% CI = 95% confidence interval, Meta P-value is generated from the Metal tool by meta-analyzing 969,689 samples from 21 independent contributing studies.

**Supplemental Table S4. Significant genes associated with severe COVID-19 identified by MAGMA gene-based association analysis**

Gene name	CHR	Start POS	Stop POS	Number of SNPs	Z score	P value	FDR
<i>LZTFL1</i>	3	45844808	45977216	314	13.14	1.01E-39	1.93E-35
<i>FYCO1</i>	3	45939391	46057316	331	11.15	3.67E-29	3.51E-25
<i>XCRI</i>	3	46042291	46088979	165	10.28	4.36E-25	2.78E-21
<i>CXCR6</i>	3	45964973	46009845	120	9.91	1.86E-23	8.90E-20
<i>CCR9</i>	3	45907996	45964667	152	9.19	2.01E-20	7.69E-17
<i>SLC6A20</i>	3	45776941	45858039	208	7.33	1.19E-13	3.80E-10
<i>CCR3</i>	3	46263872	46328197	214	7.19	3.35E-13	9.16E-10
<i>CCRI</i>	3	46223200	46269832	177	7.00	1.30E-12	3.11E-09
<i>IFNAR2</i>	21	34582231	34656831	221	6.83	4.21E-12	8.95E-09
<i>CCR2</i>	3	46375235	46422413	136	6.53	3.26E-11	6.24E-08
<i>CCR5</i>	3	46391633	46437697	133	5.69	6.28E-09	1.01E-05
<i>OAS3</i>	12	113356249	113431056	265	5.69	6.35E-09	1.01E-05
<i>OAS1</i>	12	113324739	113377712	157	5.28	6.57E-08	9.67E-05
<i>SPPL2C</i>	17	43902256	43944438	281	4.63	1.81E-06	2.47E-03

<i>CRHR1</i>	17	43677710	43933194	1203	4.59	2.24E-06	2.86E-03
<i>STH</i>	17	44056616	44097060	225	4.57	2.43E-06	2.91E-03
<i>MAPT</i>	17	43951702	44125700	901	4.41	5.09E-06	5.73E-03
<i>UBE2D1</i>	10	60074739	60150513	188	4.40	5.44E-06	5.78E-03
<i>KANSL1</i>	17	44087282	44322740	941	4.20	1.35E-05	1.36E-02
<i>TFAM</i>	10	60124903	60178990	145	4.02	2.94E-05	2.81E-02
<i>CCRL2</i>	3	46428721	46474488	195	3.99	3.33E-05	3.03E-02
<i>IBA57</i>	1	228333429	228389958	118	3.98	3.52E-05	3.06E-02
<i>IL10RB</i>	21	34618665	34689539	230	3.92	4.36E-05	3.63E-02
<i>COX10</i>	17	13952719	14131996	549	3.87	5.37E-05	4.28E-02
<i>NCR2</i>	6	41283528	41338625	328	3.83	6.32E-05	4.84E-02

**Note:** SNP =single nucleotide polymorphism, CHR = chromosome, POS = position, FDR = False discovery rate.

**Supplemental Table S5. Significant enriched pathways associated with severe COVID-19 identified from MAGMA-based pathway enrichment analysis**

ID	KEGG ID	Pathway names	Number of genes	Beta	SE	P value
1	hsa00533	Glycosaminoglycan biosynthesis - keratan sulfate	14	0.66	0.20	5.84E-04
2	hsa05168	Herpes simplex virus 1 infection	183	0.16	0.06	2.13E-03
3	hsa00601	Glycosphingolipid biosynthesis - lacto and neolacto series	27	0.43	0.15	2.69E-03
4	hsa04390	Hippo signaling pathway	153	0.17	0.06	2.87E-03
5	hsa05162	Measles	131	0.19	0.07	3.13E-03
6	hsa05164	Influenza A	167	0.15	0.06	6.36E-03
7	hsa04064	NF-kappa B signaling pathway	92	0.19	0.08	9.44E-03
8	hsa04621	NOD-like receptor signaling pathway	167	0.13	0.06	1.11E-02
9	hsa04625	C-type lectin receptor signaling pathway	104	0.16	0.07	1.13E-02
10	hsa05143	African trypanosomiasis	34	0.28	0.12	1.33E-02
11	hsa05160	Hepatitis C	131	0.14	0.07	1.63E-02
12	hsa04392	Hippo signaling pathway - multiple species	28	0.28	0.13	1.80E-02
13	hsa00603	Glycosphingolipid biosynthesis - globo and isoglobo series	15	0.48	0.23	1.81E-02
14	hsa04137	Mitophagy - animal	64	0.17	0.08	1.87E-02
15	hsa04630	JAK-STAT signaling pathway	158	0.12	0.07	3.50E-02
16	hsa04668	TNF signaling pathway	110	0.13	0.07	3.95E-02

17	hsa00471	D-Glutamine and D-glutamate metabolism	5	0.57	0.34	4.47E-02
18	hsa04060	Cytokine-cytokine receptor interaction	286	0.09	0.05	4.67E-02
19	hsa05132	Salmonella infection	81	0.14	0.09	4.92E-02

**Supplemental Table S6. The 16 significant genes associated with severe COVID-19 identified by S-MultiXcan analysis based on 49 tissues from GTEx consortium**

Gene name	CHR	START	STOP	P value	FDR
<i>LZTFL1</i>	chr3	45864808	45957216	1.08E-30	2.41E-26
<i>SLC6A20</i>	chr3	45796941	45838039	2.19E-29	2.44E-25
<i>CCR9</i>	chr3	45927996	45944667	4.16E-29	3.10E-25
<i>CXCR6</i>	chr3	45984973	45989845	1.56E-28	8.71E-25
<i>XCR1</i>	chr3	46062291	46068979	4.20E-16	1.88E-12
<i>FYCO1</i>	chr3	45959391	46037316	1.53E-14	5.69E-11
<i>CCR3</i>	chr3	46283872	46308197	8.15E-13	2.60E-09
<i>CCR1</i>	chr3	46243200	46249832	1.13E-11	3.15E-08
<i>DNAH3</i>	chr16	20944476	21170762	4.44E-10	1.10E-06
<i>CCR2</i>	chr3	46395235	46402413	1.16E-09	2.59E-06
<i>ABO</i>	chr9	136130563	136150630	1.36E-07	2.76E-04
<i>IFNAR2</i>	chr21	34602231	34636831	3.28E-07	6.10E-04
<i>IL10RB</i>	chr21	34638665	34669539	8.28E-07	1.42E-03
<i>CCR5</i>	chr3	46411633	46417697	1.22E-06	1.95E-03
<i>OAS3</i>	chr12	113376249	113411056	2.83E-06	4.21E-03
<i>CCRL2</i>	chr3	46448721	46454488	4.61E-06	6.43E-03

**Note:** CHR = chromosome, START = start position on chromosome, STOP = stop position on chromosome, FDR = False discovery rate.

**Supplemental Table S7. The eight significant genes associated with severe COVID-19 identified by S-PrediXcan analysis based on lung and blood tissues**

Gene name	CHR	START	STOP	Z score	P value	FDR	Tissue
<i>CCR9</i>	chr3	45927996	45944667	11.69	1.47E-31	1.79E-27	Blood
<i>PGLS</i>	chr19	17622278	17632097	-4.64	3.43E-06	2.09E-02	Blood
<i>CXCR6</i>	chr3	45984973	45989845	-10.55	5.10E-26	7.41E-22	Lung

<i>CCR5</i>	chr3	46411633	46417697	-5.46	4.85E-08	3.52E-04	Lung
<i>FOXP4</i>	chr6	41514164	41570122	4.88	1.08E-06	5.23E-03	Lung
<i>IL10RB</i>	chr21	34638665	34669539	4.74	2.19E-06	7.95E-03	Lung
<i>FYCO1</i>	chr3	45959391	46037316	4.65	3.35E-06	8.45E-03	Lung
<i>ABO</i>	chr9	136130563	136150630	4.64	3.49E-06	8.45E-03	Lung

**Note:** CHR = chromosome, START = start position on chromosome, STOP = stop position on chromosome, FDR = False discovery rate.

**Supplemental Table S8. The biological pathways enriched by 34 risk genes associated with severe COVID-19**

ID	KEGG ID	Pathway names	Number of genes	Ratio	P Value	FDR
1	hsa04060	Cytokine-cytokine receptor interaction	294	10.89	3.89E-08	1.27E-05
2	hsa04062	Chemokine signaling pathway	189	13.17	5.12E-07	8.35E-05
3	hsa05160	Hepatitis C	131	10.86	4.29E-04	3.60E-02
4	hsa05162	Measles	132	10.78	4.42E-04	3.60E-02
5	hsa04621	NOD-like receptor signaling pathway	168	8.47	1.10E-03	6.36E-02
6	hsa05164	Influenza A	171	8.32	1.17E-03	6.36E-02
7	hsa05168	Herpes simplex infection	185	7.69	1.57E-03	6.51E-02
8	hsa05167	Kaposi sarcoma-associated herpesvirus infection	186	7.65	1.60E-03	6.51E-02
9	hsa05169	Epstein-Barr virus infection	201	7.08	2.13E-03	0.077
10	hsa05163	Human cytomegalovirus infection	225	6.32	3.20E-03	0.104

**Supplemental Table S9. The percentage of three severe COVID-19-risk genes expressed in all 13 distinct cell types in PBMCs**

Cell types	<i>CXCR6</i>	<i>CCR1</i>	<i>ABO</i>
Effector CD8+T cells	0.007	0.008	0.002

Memory CD8+T cells	0.021	0.014	0.004
Naive CD8+T cells	0.013	0.01	0.003
Naive CD4+T cells	3.08E-04	0.001	0.012
Memory CD4+T cells	0.004	0.002	0.014
CD14+ monocytes	8.84E-05	0.099	0.002
CD16+ monocytes	2.42E-04	0.079	0.002
NK	3.19E-03	0.012	0.001
Naive B cells	3.27E-04	0.004	0.007
Dendritic cells	1.63E-04	0.051	0.007
Megakaryocytes	1.64E-03	0.004	0.112
CD34+Progenitors	1.17E-03	0.011	0.039
Mature B cells	0	0.024	0

428

429

430

**Supplemental Table S10. Summary of inflammatory and cytokine-related genes and genes in two identified KEGG pathways**

Categories	Gene lists	Resources
Inflammatory-related genes	<i>ABCA1, ABII, ACVR1B, ACVR2A, ADGRE1, ADM, ADORA2B, ADRM1, AHR, APLNR, AQP9, ATP2A2, ATP2B1, ATP2C1, AXL, BDKRB1, BEST1, BST2, BTG2, C3AR1, C5AR1, CALCRL, CCL17, CCL2, CCL20, CCL22, CCL24, CCL5, CCL7, CCR7, CCRL2, CD14, CD40, CD48, CD55, CD69, CD70, CD82, CDKN1A, CHST2, CLEC5A, CMKLR1, CSF1, CSF3, CSF3R, CX3CLI, CXCL10, CXCL11, CXCL6, CXCL8, CXCL9, CXCR6, CYBB, DCBLD2, EBI3, EDN1, EIF2AK2, EMP3, EREG, F3, FFAR2, FPR1, FZD5, GABBRI, GCH1, GNA15, GNAI3, GPIBA, GPC3, GPR132, GPR183, HAS2, HBEGF, HIF1A, HPN, HRH1, ICAM1, ICAM4, ICOSLG, IFITM1, IFNAR1, IFNGR2, IL10, IL10RA, IL12B, IL15, IL15RA, IL18, IL18R1, IL18RAP, IL1A, IL1B, IL1R1, IL2RB, IL4R, IL6, IL7R, INHBA, IRAK2, IRF1, IRF7, ITGA5, ITGB3, ITGB8, KCNA3, KCNJ2, KCNMB2, KIF1B, KLF6, LAMP3, LCK, LCP2, LDLR, LIF, LPAR1, LTA, LY6E, LYN, MARCO, MEFV, MEP1A, MET, MMP14, MSRI, MXD1, MYC, NAMPT, NDP, NFKB1, NFKBIA, NLRP3, NMI, NMURI, NOD2, NPFFR2, OLR1, OPRK1, OSM, OSMR, P2RX4, P2RX7, P2RY2, PCDH7, PDE4B, PDPN, PIK3R5, PLAUR, PROK2, PSEN1, PTAFR, PTGER2, PTGER4, PTGIR, PTPRE, PVR, RAF1, RASGRP1, RELA, RGS1, RGS16, RHOG, RIPK2, RNF144B, ROS1, RTP4, SCARF1, SCN1B, SELE, SELENOS, SELL, SEMA4D, SERPINE1, SGMS2, SLAMF1, SLC11A2, SLC1A2, SLC28A2, SLC31A1, SLC31A2, SLC4A4, SLC7A1, SLC7A2, SPHK1, SRI, STAB1, TACRI,</i>	PMID: 33657410

	<i>TACR3, TAPBP, TIMP1, TLR1, TLR2, TLR3, TNFAIP6, TNFRSF1B, TNFRSF9, TNFSF10, TNFSF15, TNFSF9, TPBG, VIP</i>	
Cytokine-related genes	<i>IL2, IL7, CSF3, CXCL10, CCL2, CCL3, TNF, TFTN1, IL6</i>	PMID: 32192578
Cytokine-related genes	<i>CXCL10, CCL7, IL1RN, CSF1, IFNG, IL6, IL2RA, IL10, IL18, HGF, CXCL9, CSF3, CCL3, CCL27</i>	Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome, 2020.3, <i>MedRxiv</i>
Cytokine-related genes	<i>TGFB1</i>	PMID: 32346099
Cytokine-related genes	<i>IL1B, LTA, IFNG, CSF1, CSF2, LTB, IL6, TNFSF13, IL18, IL2, IL4</i>	PMID: 32377375
Cytokine-related genes	<i>IL1B, IL18, IL6, TNF, CCL2, CCL7, CCL12, CXCL8, CCL3, CXCL9, CXCL10, CXCL11</i>	PMID: 32505227
Cytokine-related genes	<i>IL1B, IL6, TNF, CCL2, CCL3, CCL4, CCL7, CXCL9, CXCL10, CXCL11, CXCL1, CXCL2, CXCL3, CXCL8, CCL3L1, CCL8, CXCL16</i>	PMID: 32398875
Cytokine-related genes	<i>IL6, CXCL8</i>	PMID: 32434211
Cytokine-related genes	<i>CSF2, IL6, IFNG</i>	Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients, 2020.6, National Science Review
Cytokine-related genes	<i>IL6, IL10, CXCL8, CXCL10, IFNG, IFNA1</i>	A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis., 2020.6, medRxiv
Cytokine-related genes	<i>CXCL10, CXCL9, CCL2, IL1RN, CCL5, CCL11, TNF, HGF, IFNA2</i>	PMID: 32669297
Cytokine-related genes	<i>TNF, IL1B, IL18</i>	PMID: 32651212
Cytokine-related genes	<i>TNF, CCL3, CCL4, CCL20, IL1B, IL6, IL10, CXCL2, CXCL3, CXCL8, CXCL9, CCL3L1, CCL4L2</i>	PMID: 32764665
Cytokine-related genes	<i>IL6, CXCL10, CCL7, HGF, OSM, TNFSF14, IFNA1, SAI00A12, FGF19, CXCL5, CCL4, CCL8, CCL19, CXCL11, CCL3, IL18RI, CSF1, TNF, CCL20, TGFA, IFNB1</i>	PMID: 32788292

Cytokine-related genes	<i>TNF</i>	PMID: 32877699
Cytokine-related genes	<i>IL6, IL8, TNF, IL1B</i>	PMID: 32839624
Cytokine-related genes	<i>IL17C, TNFSF10, FGF7, XCLI, FGF13, LIF, TGFB3, INHBE, CERS1, TXLNA, IFNW1, IL22, XCL2, CCL25, CCL16, CD40LG, IL20, FASLG, TPO, SCYL3, PF4V1, TNFSF8, GDF15, IL1A, VEGFA, GDF7, BMP6, PDGFA, IL21, ABCD-1, ABCD-2, PDGFB, TNFSF4, FAM19A1, HBEGF, PDGFD, IL12RB2, GH1, VEGFB, MIP3B, IL27, PF4, BMP8B, TNFSF12, IL15, SCYL2, SCYL1, TSLP, GDF11, SDF1B, INHBA, PPBP, FGF11, IFNG-AS1, FGF22, VEGFC, CCL18, TNFSF11, IL12A, EB13, AMH, IL26, IL32, PDGFC, FGF23, IGF1, IL1F11, CCL28, CLCF1, TNFSF9, BMP3, IL24, GDF10, CXCL6, GDF9, IL23A, IL16, CD70, IL5, FGF9, IFNLI, TSC1, FGF2, IL23R, IL1G, SPP1, IL12RBI, BMP4, IL13, TPARI, TGFB2, FAM19A2, AGIF3, EDA, MIF, TNFSF13B, BMP7, FGF18, CCL23</i>	KEGG database (PMID: 10592173)
Genes in the KEGG pathway of cytokine-cytokine receptor interaction (hsa04060)	<i>GDF11, CCL26, CXCL13, CXCR6, TNFSF13B, CCR9, CCL27, EDAR, IL24, IL17F, TNFRSF13C, CCRI, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CNTF, CNTRF, ACVR1C, IL17RE, IL31RA, CSF1, CSF1R, CSF2, CSF2RB, CSF3, CSF3R, CSH1, CSH2, IL34, CTF1, IL23R, GDF7, CX3CR1, IFNLR1, EDA, EPO, EPOR, TNFRSF13B, CLCF1, IL17RA, IL27, IL36RN, GDF1, GDF2, MSTN, GDF9, GDF10, AMH, GH1, GH2, AMHR2, GHR, IL36B, IL37, IL36A, IL17C, IL17B, TNFRSF21, BMP10, CCR10, IFNL2, IFNL3, IFNLI, XCR1, CXCR3, CXCL17, CXCL1, CXCL2, CXCL3, IL19, IFNE, IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21, IFNAR1, IFNAR2, IFNB1, IFNG, IFNGR1, IFNGR2, IFNW1, BMP8A, FAS, IL1A, IL1B, IL1R1, IL1RAP, IL1RN, IL2, IL2RA, FASLG, IL2RB, IL2RG, IL3, IL4, IL4R, IL5, IL5RA, IL6, IL6R, IL6ST, IL7, IL7R, CXCL8, CXCR1, IL9, CXCR2, IL10, IL10RA, IL10RB, IL11, IL11RA, IL12A, IL12B, IL12RBI, IL12RB2, IL13, IL13RA1, IL13RA2, IL15, IL15RA, IL16, TNFRSF9, IL17A, IL18, INHA, INHBA, INHBB, INHBC, CXCL10, IL31, CCL4L1, GDF6, LEP, LEPR, LIF, LIFR, LTA, LTB, LTBR, CCL3L3, CXCL9, MPL, NGF, NGFR, NODAL, TNFRSF11B, OSM, IL20, IL21R, IL22, TNFRSF12A, ACKR4, IL23A, PF4, PF4V1, IL17D, IL20RA, IL20RB, PPBP, TNFRSF19, IL17RB, IL26, PRL, PRLR, IL36G, CCL28, IFNK, ACKR3, CXCL16, IL22RA1, IL21, EDA2R, TNFRSF17, CCLI, CCL2, CCL3, CCL3L1, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CXCL6, CXCL11, CXCL5, XCL1, CX3CL1, CXCL12, CXCR5, IL25, BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8B, BMPR1A, BMPR1B, BMPR2, XCL2, TGFB1, TGFB2, TGFB3, TGFBRI, TGFBRI2, THPO, TNF, TNFRSF1A, TNFRSF1B, TNFSF4, CCR2, TNFRSF4, IL1R2, CXCR4, GDF5, INHBE, IL1F10, IL17RC, RELT, TSLP, TNFSF11, TNFRSF25, TNFSF14, TNFSF13, TNFSF12, TNFSF10, TNFSF9, TNFRSF14, TNFRSF6B, TNFRSF18, TNFRSF11A, TNFRSF10D, TNFRSF10C, TNFRSF10B, TNFRSF10A, IL18RAP, IL1RL2, IL18R1, TNFSF18, ACVR1, IL33, ACVR1B, IL1RL1, OSMR, ACVR2A, CD4, BMP15, IL32, ACVR2B, CD27, ACVRL1, TNFRSF8, TNFSF8, IL27RA, GDF15, CXCL14, CCL4L2, GDF3, CD40, CD40LG, CD70, TNFSF15</i>	KEGG database (PMID: 10592173)
Genes in the KEGG pathway of chemokine signaling pathway (hsa04062)	<i>AKT3, RASGRP2, CCL26, VAV3, CXCL13, CXCR6, GNB5, ADCY1, ADCY2, CCR9, CCL27, ADCY3, ADCY5, ADCY6, ADCY7, ADCY8, CHUK, ADCY9, CCRI, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, GRK7, CRK, CRKL, PIK3R6, CX3CR1, ADRBK1, ADRBK2, DOCK2, ADCY4, AKT1, AKT2, PTK2B, FGR, FOXO3, PLCB1, PIK3R5, SHC2, GNAI1, GNAI2, GNAI3, GNB1, GNB2, GNB3, GNG3, GNG4, GNG5, GNG7, GNG10, GNG11, NGGT1, NGGT2, CCR10, XCR1, CXCR3, GRK4, GRK5, GRK6, GRB2, CXCL1, CXCL2, CXCL3, GSK3A, GSK3B, HCK, HRAS, IKBKB, CXCL8, CXCR1, CXCR2, CXCL10, ITK, JAK2, JAK3, KRAS, RHOA, CCL4L1, SHC4, LYN, ARRB1, ARRB2, CCL3L3, CXCL9, NFKB1, NFKBIA, NFKBIB, NRAS, PAK1, GNG13, PF4, PF4V1, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PLCB2, PLCB3, PLCB4, SHC3, GNG2, PPBP, PRKACA, PRKACB, PRKACG, PRKCB, PRKCD, PRKCZ, MAPK1, MAPK3, GNG12, MAP2K1, PARD3, CCL28, BAD, PTK2, PREX1, CXCL16, PXN, RAC1, RAC2, RAF1, RAPIA, RAPIB, GNB4, RELA, ROCK1, CCL1, CCL2, CCL3, CCL3L1, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CXCL6, CXCL11, CXCL5, XCL1, CX3CL1, CXCL12, CXCR5, SHC1, NCF1, SOS1, SOS2, SRC, BRAF, STAT1, STAT2, STAT3, STAT5B, XCL2, TIAMI, CCR2, VAV1, VAV2, WAS, CXCR4, PIK3R3, IKBKG, WASL, GNG8, ROCK2, CXCL14, CCL4L2, BCARI, ELMO1, CDC42</i>	KEGG database (PMID: 10592173)

431  
432  
433

**Supplemental Table S11. Highly-expressed inflammatory and cytokine genes among *CCR1+* *CD16+* monocytes**

Gene	T score	Fold change	P value	FDR
<i>ADM</i>	6.26	1.72	5.17E-10	2.97E-08
<i>AHR</i>	5.16	1.71	2.83E-07	1.07E-05
<i>AQP9</i>	5.70	1.96	1.47E-08	7.07E-07
<i>C3AR1</i>	6.30	1.56	3.99E-10	2.31E-08
<i>CCL3</i>	6.16	1.55	9.43E-10	5.26E-08
<i>CCL3L1</i>	5.57	1.71	3.01E-08	1.37E-06
<i>CCL4L2</i>	3.06	1.92	2.28E-03	2.49E-02
<i>CD14</i>	18.55	2.14	2.02E-68	1.57E-64
<i>CD82</i>	3.98	1.59	7.16E-05	1.43E-03
<i>CSF3R</i>	7.18	1.56	1.16E-12	9.94E-11
<i>CXCL10</i>	4.17	3.36	3.29E-05	7.14E-04
<i>CXCL2</i>	7.12	2.72	1.83E-12	1.53E-10
<i>CXCL3</i>	3.33	3.33	9.03E-04	1.19E-02
<i>CXCL8</i>	5.56	1.52	3.29E-08	1.48E-06
<i>EIF2AK2</i>	7.87	1.95	7.19E-15	7.88E-13
<i>EREG</i>	6.05	2.02	1.92E-09	1.02E-07
<i>FFAR2</i>	5.56	1.92	3.29E-08	1.48E-06
<i>FPRI</i>	10.14	1.53	2.60E-23	5.69E-21
<i>GPR183</i>	2.99	1.69	2.85E-03	2.99E-02
<i>HBEGF</i>	4.55	1.70	5.84E-06	1.57E-04
<i>IL1B</i>	6.66	1.58	3.89E-11	2.65E-09
<i>IL1RN</i>	8.87	2.68	2.54E-18	3.63E-16
<i>IL27</i>	2.90	2.73	3.75E-03	3.67E-02
<i>IL4R</i>	3.29	1.58	1.04E-03	1.33E-02
<i>ITGA5</i>	2.85	1.53	4.39E-03	4.17E-02
<i>LDLR</i>	4.06	1.72	5.11E-05	1.05E-03
<i>MARCO</i>	7.60	1.66	5.50E-14	5.44E-12



<i>MYC</i>	3.12	1.90	1.83E-03	2.11E-02
<i>NLRP3</i>	4.92	1.61	9.51E-07	3.16E-05
<i>OSM</i>	2.92	1.82	3.53E-03	3.51E-02
<i>PTAFR</i>	6.99	1.85	4.44E-12	3.42E-10
<i>RTP4</i>	3.35	1.80	8.32E-04	1.11E-02
<i>SELL</i>	9.16	1.94	1.92E-19	3.18E-17
<i>SPHK1</i>	4.81	2.25	1.71E-06	5.32E-05
<i>STAB1</i>	7.78	2.40	1.56E-14	1.65E-12
<i>TNFAIP6</i>	3.44	3.33	5.94E-04	8.43E-03
<i>CCL2</i>	3.36	5.74	8.08E-04	1.08E-02

434

435

436

**Supplemental Table S12. Pathway enrichment analysis of 351 highly-expressed genes among *CCR1*+ *CD16*+ monocytes.**

Pathway name	Gene size	Enrichment ratio	P Value	FDR
NOD-like receptor signaling pathway	168	4.25	4.32E-07	9.07E-05
Influenza A	171	4.17	5.56E-07	9.07E-05
Cytokine-cytokine receptor interaction	294	3.14	1.61E-06	1.75E-04
Hematopoietic cell lineage	97	5.19	2.83E-06	2.31E-04
Pertussis	76	5.52	1.12E-05	7.32E-04
Salmonella infection	86	4.88	3.39E-05	1.84E-03
Legionellosis	55	6.10	4.16E-05	1.94E-03
Staphylococcus aureus infection	56	5.99	4.75E-05	1.94E-03
Complement and coagulation cascades	79	4.78	9.93E-05	3.60E-03
Toll-like receptor signaling pathway	104	4.03	1.73E-04	5.63E-03
TNF signaling pathway	110	3.81	2.74E-04	8.13E-03
NF-kappa B signaling pathway	95	3.98	4.09E-04	1.11E-02

Malaria	49	5.14	1.01E-03	2.52E-02
Hepatitis C	131	3.20	1.10E-03	2.56E-02
Herpes simplex infection	185	2.72	1.50E-03	3.26E-02
Chemokine signaling pathway	189	2.66	1.80E-03	3.67E-02
Amoebiasis	96	3.50	1.98E-03	3.79E-02
Human cytomegalovirus infection	225	2.42	2.71E-03	4.91E-02
Chagas disease (American trypanosomiasis)	102	3.29	2.90E-03	4.97E-02
Phagosome	152	2.76	3.32E-03	5.42E-02
Cytosolic DNA-sensing pathway	63	4.00	3.71E-03	5.77E-02
Measles	132	2.86	4.16E-03	6.17E-02
Transcriptional misregulation in cancer	186	2.48	4.78E-03	6.77E-02
IL-17 signaling pathway	93	3.16	6.57E-03	8.92E-02
Glycosaminoglycan degradation	19	6.63	9.74E-03	1.27E-01
JAK-STAT signaling pathway	162	2.33	1.51E-02	1.90E-01
Bladder cancer	41	4.09	1.59E-02	1.92E-01
Acute myeloid leukemia	66	3.18	2.01E-02	2.19E-01
Inflammatory bowel disease (IBD)	65	3.23	1.90E-02	2.19E-01
Rheumatoid arthritis	90	2.80	2.01E-02	2.19E-01
RIG-I-like receptor signaling pathway	70	3.00	2.53E-02	2.66E-01
Tuberculosis	179	2.11	2.70E-02	2.75E-01
Nicotinate and nicotinamide metabolism	30	4.20	3.37E-02	2.97E-01
PPAR signaling pathway	74	2.84	3.12E-02	2.97E-01
Osteoclast differentiation	128	2.29	3.29E-02	2.97E-01
Leishmaniasis	74	2.84	3.12E-02	2.97E-01
Kaposi sarcoma-associated herpesvirus infection	186	2.03	3.34E-02	2.97E-01

Antifolate resistance	31	4.06	3.67E-02	3.15E-01
Th17 cell differentiation	107	2.35	4.22E-02	3.52E-01
Glycosphingolipid biosynthesis	15	5.59	4.84E-02	3.85E-01

437

438

### Supplemental Table S13. Druggable proteins collected from the ChEMBL database

Categories	Protein lists	Resources
1,263 human druggable proteins	<p><i>HGNC_SYMBOL, HTR3E, PSMD12, PLK4, PIK3R2, PSMD14, MSTN, PSMA7, XPO1, DCLK1, PLA2G10, PDPK1, CYP26A1, MLNR, MGAM, HCRTR2, CACNA1F, BRD4, NR1I2, GMNN, STK16, TRPA1, DGAT1, PAK3, HTR3B, BMP10, ABCA1, ABHD16A, F8, F9, TNF, IFNA1, IFNG, IGHE, FNI, TTR, CXCL10, CSF2, MASI, CD74, CD3D, SHBG, TRAV29DV5, IGF1, CYP17A1, IL5, SERPINE1, CYP1A2, IL6, LCK, CDK1, CD2, CEACAM5, CALCA, LIPF, TUBB, CHRM4, SERPINA6, MMP2, PTPRC, MYL3, HCK, CYP3A4, CYP21A2, HTR1A, CD3G, ALOX5, WEE2, CD28, RARB, THRA, MYL2, HSPA8, CHRM1, PIMI, TOP1, TOP2A, DMD, CDK4, IMPDH2, FCGR1A, SRC, MYH6, RARG, ADRB3, FOLR2, SI, INSR, PKM, TYR, GABRA1, IFNGR1, FOLR1, CD19, ELN, CYP11B1, PNLIP, ENG, FLT1, ADRA2B, GABRB1, GABRG2, CYP11B2, RXRA, ERBB3, GART, CDH3, CA4, MMP8, PPIB, EDNRB, HRH2, BRD2, PSMA1, PSMA3, HSD3B2, CD27, PIK3R1, PSMB8, PSMB9, PSMB4, PSMB6, RXRB, HSD11B1, CTGF, CD40LG, AVPR2, CALCR, SRD5A2, SSTR3, CNR2, TRHR, PTGS2, OPRM1, SCN4A, PDE6B, IFNGR2, THPO, MPL, ADH7, CASR, GRM5, MC3R, AKR1C3, PIK3CA, CA7, NR4A2, KIR2DL1, KIR2DL2, KIR2DL3, PSMC4, TNNT2, MMP13, NOTCH1, AVPR1B, MTNR1A, CSNK1A1, PIK3CG, MAPKAPK2, PSMB3, CLK1, CLK2, GSK3A, AGTR2, CDK7, IRAK1, PSMD7, CCR4, CCR9, BMX, KIF11, EPHB3, LOXL3, PSMC1, RBX1, TNNC1, TUBA4A, TUBB4B, HBB, HBA1, HBA2, PIP4K2B, HAMP, MUC5AC, CDK6, CDK5, CDK17, NFKB2, SCN7A, FKBP4, KMT2A, RELA, NOTCH2, ACVR1, GRIN1, BTK, LTB, PDE4B, PDE4D, MAP4K2, SLC10A2, GRIN2B, PDE3B, FKBP5, PRPF4B, HTR4, NCOA4, IKBKE, IL13RA2, MELK, NR1I3, EBP, SHH, MYLK, KCNJ8, ADRM1, NFE2L2, RPE65, DDB1, BCL2A1, IL17A, CYP2A13, AOC3, MGAM2, HLA-DRB1, MYLK3, SLC22A6, SLC44A4, TMEM97, TUBA1A, MARK2, SV2A, KCNK18, TPH2, PSMA8, SLC22A8, MAPK15, HDAC2, BCL2L2-PABPN1, GHSR, MAP4K1, APH1A, AURKB, SLC46A1, PVRL4, TAARI, HBEGF, HSD17B10, TSSK1B, HDAC8, FGF23, IL22, HIPK3, CYP3A43, CD248, PDE7B, TNFRSF12A, KCNK9, DLL4, PSENNEN, PIM2, HDAC6, GABBR1, GDF2, CA14, NOTCH3, GABRQ, SRPK3, AKT3, HCN4, ANGPTL3, HRH3, SCN10A, ICOS, TNFSF11, TNFSF14, LTA, CD4, MMP3, IL8, PDGFRA, TNFRSF9, DDR1, GLA, NCAM1, HGF, IL6ST, AKR1C1, MPO, IL12B, IL5RA, PSMB11, MYH7B, PSMD11, BMPR1B, CDC7, PIK3CD, STK25, FAAH, CACNA1A, GABRP, KCNK3, RIOK3, TERT, CHEK1, GABRD, FFAR1, IKBKB, AURKA, GAK, NPC1, ANGPT2, HDAC3, GRIN2D, TLR3, KCNN4, PRPF4, GPR39, PSMD3, MAP3K13, DAPK3, MAP3K7, RIPK2, CACNA1G, KCNQ3, KCNQ2, CA12, HCRTR1, PSCA, PDE6D, AKR1B10, NUAK1, GRIN3B, CCNT1, PDE8A, JAK2, ABCC9, RAMP1, CTSV, FZD7, ROCK2, GUCY1B2, NCOR1, ULK1, CA11, RPS6KA5, RPS6KA4, IDH1, TNFSF13, GABBR2, PDE5A, STK10, PRKD3, KCNK2, S1PR2, CACNA1H, PDE8B, TNKS, ESRRB, MAP4K4, GLP2R, S1PR4, PAK4, CHEK2, ADH1B, ADH1C, ALDH1A1, DHFR, GSR, PAH, SOD1, PNP, ABLI, CFD, F12, PLAT, CA1, CA2, SERPINC1, C5, PDGFB, NGF, IGF2, IL1A, IL1B, TRAC, LMNA, TNNC2, FGB, CHRNA1, AFP, GC, ESRI, KLKB1, TRGV3, HMGCR, RAF1, GBA, APOB, NR3C1, TK1, VWF, TUBB4A, TRBV7-9, ERBB2, NTRK1, TP53, AMY2A, CYP1A1, TYMS, ATP1A1, ATP1B1, APP, ALDH2, ITGB3, ITGB2, CYP11A1, IL4, PRKCG, FGF1, ITGB1, PRKCB, INSR, FYN, BCHE, PGR, EIF4E, NPM1, ITGAV, TH, TPO, KLK3, H1F0, ADH1A, FES, CSF1R, CHRNG, ADRB2, CD3E, HSP90AA1, YES1, LYN, IGF1R, CHRM2, ABCB1, NR3C2, HSP90AB1, ADH4, MME, INHBA, ITGA2B, MET, ADRB1, FCGR3A, ITGA5, VIM, STS, CHRM5, ADRA2A, ROS1, FGF2, HMGB1, TACSTD2, FGR, PARP1, LTA4H, ADORA3, CALM1, TUBA3C, CALCB, GAA, AR, RARA, ARAF, BCL2, TGFB3, CYP2D6, MAPT, KIT, THRB, CD37, UMPS, ITGAM, CHRN1, BCR, FGFR1, VDR, ESRRA, CYP2A6, CYP19A1, CETP, CYP2C9, ADH5, MS4A1, ODC1, ACE, MYL4, MYH7, CCL2, CFTR, ITGA4,</i></p>	PMID: 33837377

*ATP1A3, EEF2, SLC5A1, HSD17B1, FDPS, DRD2, IL2RB, BRAF, GLUL, IL9, CSF2RA, PHKG2, MUC1, ALOX15, NPR1, CD44, CTLA4, EPCAM, DPEP1, TSHR, PDE6A, SELE, FER, PRKCA, ITGA2, PRKACA, TYRPI, TPH1, CHRN2, CR1, PSMC3, ALOX12, ITGB5, SRD5A1, PDE6G, ITGB6, ADRA2C, SDC1, EPOR, TNNI3, AOC1, NFKB1, TYMP, CD22, ALOX5AP, CHRM3, PSMB1, ATP4A, ITGAL, DDC, CYP3A5, IMPDH1, MAG, MAOA, TACR2, SIPR1, CNR1, DRD1, C5AR1, TBXA2R, FGFR2, RYR1, DRD4, DRD5, COMT, IL10, ACHE, FGFR4, FGFR3, PRKACG, PRKACB, LHCGR, PTGS1, GLRA1, RPS6KB1, JAK1, TNFSF4, CPT2, RRM1, FSHR, CMA1, SLC6A2, GABRR1, CCND1, CYP3A7, TBXAS1, PRKCH, CCNE1, CDK2, CXCR1, CXCR2, GUCY2C, ADRA1D, EDNRA, TACR1, PTAFR, PSMA2, PSMA4, ITGB7, DNMT1, IL3RA, MAOB, MAPK3, MARK3, DPP4, PDE4A, PSMA5, PSMB5, HTR1D, HTR1B, HTR2A, ADH6, HTR2C, GABRB3, MAPK1, TNFRSF8, IMPA1, ADORA2A, ADORA2B, EPHA2, EPHA3, EPHA8, TACR3, LTK, CASP1, TYK2, CD6, CCND2, CCND3, WEE1, BDKRB2, SLC6A1, CHRNA5, TSPO, ADORA1, AGTR1, OXTR, SSTR1, SSTR2, CHRN4, HTR1F, GNRHR, NTSR1, CPS1, RRM2, CD52, SSTR4, SLC5A2, GABRA5, SLC6A4, AKT1, AKT2, ATIC, CCKAR, CCKBR, MC4R, CCR1, CHRNA3, GRK4, HPD, ICAM3, CD70, MC5R, KIF5B, CYP2C19, GUCY1A2, ABCC1, CD80, TTK, GABRA3, EPHX2, HTR7, PTGER1, CRHR1, IL13, SSTR5, ADRA1A, HRH1, ADRA1B, PTGER4, DRD3, SCN1A, SOAT1, BSG, CHKA, PSMC2, MAP2K2, CHRNA7, FLT3, TGFBRI, SCNN1A, PPARG, FDFT1, AVPR1A, GGCX, GRIK1, PLA2G5, CD79B, PSMB10, IL15, PMEL, OPRD1, OPRK1, OPR1, P2RY2, HNF4A, CSK, IARS, SLC19A1, HTR2B, CCR2, PRKCI, CD86, GRIA1, GRIA2, GRIA3, PIK3CB, MTOR, TEC, TXK, ABL2, FRK, HTT, PTGFR, PTGER3, PTGER2, PTGIR, MCAM, GLP1R, CTSK, GPD2, SYK, TNFRSF4, NAMPT, CHRNA4, TNNT3, MAPK8, MAPK9, RECQL, HTR3A, BDKRB1, GABRA2, GABRB2, GCGR, SCTR, HTR5A, XDH, GRIA4, SLC6A9, GABRA4, RXRG, IFNAR2, PSMD8, CSNK1D, IDH2, SLC9A3, TNNI2, MTNR1B, CDK8, FNTA, FNTB, CSNK1E, PSMB2, PGF, VEGFB, PSEN1, PSEN2, GSK3B, DIO1, NPY4R, HTR6, CDK9, ATP1A2, RAB9A, PDE6C, ATP4B, SCNN1B, SCNN1G, RORC, BLK, CYP2J2, ALDH5A1, CCL11, CCR5, KCNQ1, CLCN2, RPS6KA3, JAK3, PLK1, DAPK1, COL4A4, LIMK2, MAPK12, MAPK10, BLM, CACNA2D1, PRKAA2, ATP1B3, FXD2, EPHA5, EPHB1, EPHA4, SLC12A3, PSMD4, NR1H2, MTPP, CASP9, GFER, P2RX3, HDAC4, KCNQ4, BACE1, CLDN18, SIK1, KCNK10, SHFM1, PSMA6, CXCR4, TGFB2, PSMC5, PSMC6, ESRRG, PPIA, FKBP1A, KCNJ2, FKBP1B, TUBA1B, CSNK2A1, GABRE, SRPK2, PRKDC, ADAM17, IL13RA1, MAP3K9, HSD11B2, ABAT, CDK16, CACNA1B, MDM2, MYL7, PMP22, MYT1, CACNA1D, MC2R, MC1R, SLC6A3, GUCY1A3, DHODH, GUCY1B3, PRKCE, RHD, GHRHR, MAP2K1, MAP3K10, TOP2B, PPAR, PTH1R, FOLH1, PRKCQ, CHRNE, MST1R, PTK2, PRKCZ, PRKCD, CHRN3, SLC18A2, PPAT, AOX1, TYRO3, CHRN, BCL2L1, MCL1, PPARA, TNK2, CYP24A1, PPP3CA, PDE4C, PPID, ITK, DMPK, ABCC8, KCNMA1, KCNH2, MAP3K12, GRIN2A, DPYD, FAP, GRIK2, GRIK3, STK4, PLA2G7, PRKAA1, NR1H3, MAP2K5, PAK2, STK3, PSMD2, MAP3K1, PRKG2, PTGDR, GPR17, MSLN, IKZF1, ROCK1, FZD5, TNK1, MADCAM1, BIRC3, BIRC2, TUBB3, ATR, HDAC1, CAMK2G, CAMK2D, NAE1, CUL4A, SLC12A1, DYRK1A, TPBG, CACNA1S, ACVR2B, ATP1A4, BMPR2, PTK6, TUBB2A, CACNA1C, PDE7A, PDE6H, PRKG1, IL18, KEAP1, PTK2B, FZD2, GRM2, PDE3A, SCN5A, SQLE, KCNJ11, GRM3, GRIN2C, PSMD6, BRD3, PDCD1, PDK1, PDK2, PDK3, PRKD1, ERBB4, RPS6KA2, DHCR24, SF3B3, RYR3, RPS6KA1, TESK1, LTBR, MAPK11, NPY5R, CHRNA2, CHRNA6, STK11, GRK1, SCN9A, GRIK4, CCDC6, GABRA6, GRIK5, PKN1, PKN2, MAPK14, MAP3K11, CALCR, NTRK2, SMN2, PDK4, HIF1A, UGCG, CA9, PHKG1, DDR2, CYP51A1, TXNRD1, AAK1, TUBB8, PDCD4, MAP3K19, BRDT, TNNI3K, LRRK2, ANO1, CD276, TUBA3E, ULK3, NPSR1, HTR3D, TRPM8, DPP9, PIM3, MYLK4, HIPK1, IFNLR1, CAMK1D, MAP4K3, MAPKAPK5, ULK2, GABRG1, CA13, ABHD12, MINK1, DAGLB, HIPK4, TRPV1, TRPV3, UBA3, GRIN3A, STK35, HCAR2, GPBAR1, GRK7, CLEC4C, HDAC7, APH1B, HTR3C, RXFP2, MUC16, PIK3R5, CPT1B, NCSTN, PIK3R3, ESR2, RORB, BCL2L2, SLC02A1, BHMT, TSLP, TOP1MT, HDAC10, HDAC11, LINGO1, SLC47A1, LOXL4, EGLN2, NR1H4, CAMKK2, SLC22A12, SRPK1, CRBN, CSF3R, SCN2A, PSMB7, PSMD1, SIPR3, GPER, P2RX7, PKMYT1, MAP3K5, SIGMARI, PIP5K1A, MAP3K3, GPA33, SLC29A1, EPAS1, TSG101, SMO, GABRG3, SOST, VKORC1, TUBA1C, RIOK1, TUBB6, ABHD6, TUBB2B, RIOK2, EBPL, ACE2, STK33, DCLK3, EGLN1, CHRNA10, NUA2, PARP12, SIK2, MYLK2, SIPR5, P2RY12, SLK, TNKS2, TAOK3, BHMT2, HIPK2, HRH4, SRMS, FZD8, TUBB1, EGLN3, SRD5A3, CLK4, TRPV4, RXFP1, NOD2, EML4, GPR35, PDE11A,*

	<p><i>BCL2L10, IL23A, RTN4, KCNQ5, TLR9, CYSLTR2, SLC22A11, BMP2K, TDPI, IRAK4, SIRT5, P4HTM, SCN3A, CACNA2D2, SLC5A4, TLR7, MAP3K20, IL20, CISD1, CACNA1I, STK26, RCOR3, EIF2AK4, DHCR7, RPS6KB2, MALT1, STK17A, EPHA6, CHRNA9, PARP2, NPC1L1, TBK1, STEAP1, EGFL7, SCN11A, DAPK2, TNIK, UTS2R, IKZF3, HDAC9, ALK, CELA1, PSMD13, FZD1, TFR2, AURKC, SCN8A, HDAC5, CAMK2A, PDE10A, HPSE, CYSLTR1, CA5B, NISCH, SIK3, MAP3K2, DYRK1B, L3MBTL1, DAGLA, LOXL2, MAP4K5, TNFRSF18, PTGDR2, IRAK3, NCOR2, STK24, PARP3, DNMT3A, MAP3K4, TNFRSF10A, TNFRSF10B, EGFR, REN, ADA, TGFB1, IL2RA, TFRC, MMP1, CD5, MMP7, CSF1, SPP1, IL1R1, TNFRSF1A, IL4R, F2R, CD40, CD38, AXL, CA5A, LTBR, ACVRL1, CD200, SULT1A1, EPHB4, IL10RB, MERTK, CASP8, ANGPT1, NTRK3, PCSK9, CD274, TNFSF13B, F2, PLG, CD14, TLR4, NRP1, MAPK13, ICOSLG, DKK1, ICAM1, FCER2, CA3, RET, GSTP1, PDGFRB, GHR, PTHLH, TDGF1, SELL, ATP1B2, PLA2G2A, MMP9, IDO1, AKR1B1, NQO1, NQO2, CBRI, IFNARI, CD33, EPHA1, CA6, TNC, EPHB2, CSF2RB, TIE1, FLT4, KDR, SNCA, PTGDS, PRCP, LEPR, VEGFA, IL11RA, GPNMB, RRM2B, LY96, EPHB6, TNFSF12, VEGFA, SELP, MMP12, GFRA1, DLK1, TEK, PDCD1LG2, SLAMF7, F10, MFGE8, IL6R, IL17RA,</i></p>	
<p>703 human druggable proteins have evidence for involvement in COVID-19</p>	<p><i>SIGMAR1, DNMT1, SIRT5, BRD4, BRD2, IL17RA, TLR9, TLR7, ESR1, ESR2, CSNK2A1, RET, FLT3, PIK3CD, TOP2A, PIK3R1, AXL, PIK3CB, PIK3CG, EBP, ALK, PIK3R2, CCNT1, CDK1, ROS1, CDK4, CCND1, CCNE1, CDK2, CCND3, PIK3CA, CDK9, CDK6, CDK5, DHCR24, MAPK14, PIK3R5, PIK3R3, ABL1, LMNA, LYN, CHRM4, CHRM5, ADRA2A, PDGFRB, KIT, BCR, FGFR1, DRD2, PDGFRA, FLT1, ADRA2C, CHRM3, IMPDH1, FGFR2, FGFR4, FGFR3, ADRA1D, HTR2A, HTR2C, HRH1, DRD3, KDR, HTR2B, ABL2, HTR6, SMN1, SMN2, PLK4, GAK, NPC1, JAK2, CACNA1F, ROCK2, EGFR, F10, CA1, CA2, NR3C1, ERBB2, TP53, INSR, LCK, FYN, PGR, EIF4E, CSF1R, YES1, IGF1R, ABCB1, HCK, CYP3A4, FGR, RARA, RARB, CHRM1, VDR, CYP2C9, RARG, NQO2, ADRA2B, ATP4A, DRD1, DRD4, PPIB, SLC6A2, AGTR1, SLC6A4, CYP2C19, HTR7, PTGS2, OPRM1, FLT4, THPO, CSK, MTOR, TEC, TXK, PTGIR, RAB9A, BLK, BMX, JAK3, BLM, ESRRG, PPIA, FKBP1A, FKBP1B, CACNA1D, FKBP4, GRIN1, BTK, PPP3CA, DDR1, PPID, KCNH2, STK4, MAP2K5, STK3, GRIN2B, FKBP5, ROCK1, PRPF4B, CAMK2D, CACNA1S, PTK6, CACNA1C, ERBB4, CA9, DDR2, AAK1, PDCD4, MAP3K19, SLC47A1, SRPK1, EBPL, NUAK2, CLK4, TDP1, DHCR7, SRPK3, CAMK2A, RIPK2, IMPDH2, SRC, BMPR1B, AURKA, EPHB6, MAPK13, PRPF4, NUAK1, PAK4, ALDH1A1, RAF1, ATP1A1, ATP1B1, CYP17A1, PRKCB, CHRM2, MET, ARAF, CYP2D6, THRB, PIM1, CYP19A1, CFTR, ATP1A3, ATP1B2, BRAF, CYP11B2, EPHA1, ERBB3, DRD5, CPT2, MAPK3, MARK3, MAPK1, EPHA2, EPHA3, EPHA8, EPHB2, CCND2, AKT1, AKT2, EPHX2, PTGER1, SCN1A, SCN4A, TIE1, MPL, GRIA1, GRIA2, GRIA3, FRK, PTGER2, SYK, MAPK8, MAPK9, GRIA4, MAPKAPK2, CDK8, FNTA, FNTB, CDK7, ATP1A2, PLK1, LIMK2, MAPK12, MAPK10, ATP1B3, FXD2, EPHB3, EPHA5, EPHB4, EPHB1, EPHA4, SIK1, KCNJ2, MAP3K9, SCN7A, MYT1, TEK, ACVR1, TNK2, CYP24A1, PRKG2, TNK1, NAE1, DYRK1A, ATP1A4, SCN5A, TESK1, MAPK11, GRK1, SCN9A, PKN1, PKN2, MAP3K11, CYP51A1, TNNS3K, MARK2, PIM3, HIPK4, UBA3, MAPK15, GRK7, CPT1B, AURKB, CAMKK2, SCN2A, PKMYT1, RIOK2, TSSK1B, SIK2, SRMS, EML4, SCN3A, MAP3K20, PIM2, EIF2AK4, TBK1, SCN11A, SCN8A, PDE10A, AKT3, SIK3, HCN4, DYRK1B, MAP4K5, SCN10A, RBX1, IKZF1, CUL4A, DDB1, CRBN, IKZF3, KCNK3, RIOK3, XPO1, DCLK1, GRIN2D, TLR3, DAPK3, MAP3K7, CA12, PDE6D, GRIN3B, GUCY1B2, GMNN, STK16, PDE5A, STK10, KCNK2, S1PR2, ESRRB, S1PR4, DHFR, F2, PLG, REN, SERPINC1, C5, TNF, IFNG, IL1B, KLKB1, MMP1, HMGCR, CSF2, MASI, SHBG, TUBB4A, NTRK1, TYMS, ITGB3, CYP1A2, IL6, TUBB, ADRB2, SERPINA6, NR3C2, ITGA2B, CD14, ADRB1, IL6R, MMP7, HMGB1, LTA4H, ADORA3, TUBA3C, CXCL8, AR, ESRRB, ACE, SLC5A1, ADRB3, INSRR, IL1R1, CSF2RA, VEGFA, ALOX15, SELP, TSHR, PDE6A, FER, IFNARI, SRD5A1, PDE6G, NFKB1, CYP3A5, S1PR1, CNR1, GART, ACHE, MMP8, PTGS1, CA6, GLRA1, JAK1, CYP3A7, EDNRB, TBXAS1, HRH2, EDNRA, TACR1, DPP4, HTR1D, ADORA2A, ADORA2B, CCN2, TYK2, CD6, AVPR2, OXTR, GNRHR, SRD5A2, SLC5A2, ATIC, GRK4, CSF2RB, CD80, TTK, ADRA1A, ADRA1B, PDE6B, MAP2K2, AVPR1A, OPRD1, OPRK1, SLC19A1, CD86, AKR1C3, CA7, MMP13, AVPR1B, MTNR1A, IFNAR2, MTNR1B, CLK1, GSK3B, AGTR2, PDE6C, CYP2J2, CCR5, RPS6KA3, DAPK1, PRKAA2, KCNK10, TUBA1B, TUBA4A, TUBB4B, PIP4K2B, SRPK2, CDK16, CDK17, SLC6A3, DHODH, GUCY1B1, MAP2K1, TOP2B, AOX1, IL10RB, ITK, MERTK, GRIN2A, FAP, PRKAA1, TUBB3, CAMK2G, BMPR2, TUBB2A, PDE6H, PRKG1, PTK2B,</i></p>	<p>PMID: 33837377</p>

	<p><i>MELK, GRIN2C, PDCD1, RPS6KA2, SF3B3, STK11, NTRK3, IL17A, NTRK2, HIF1A, TUBB8, LRRK2, TUBA3E, AC091230.1, NPSR1, TUBA1A, KCNK18, IFNLRI, MINK1, GRIN3A, MAP4K1, S1PR3, GPER1, HSD17B10, PIP5K1A, MAP3K3, SLC29A1, TUBA1C, RIOK1, TUBB6, TUBB2B, DCLK3, S1PR5, P2RY12, SLK, TUBB1, SRD5A3, CYP3A43, KCNK9, CYSLTR2, BMP2K, SLC5A4, STK26, DAPK2, TNK1, CYSLTR1, MAP3K2, PTGDR2, GLA, COMT, BRD3, F8, IL2RA, FGB, VWF, CD2, CD3E, ALOX5, MS4A1, ITGA4, PKM, IL2RB, GLUL, IFNGR1, NQO1, ALOX12, ITGAL, CXCR1, CXCR2, F2R, ITGB7, HSD3B2, PDE4A, IL12B, CD52, PPARG, IFNGR2, CCR2, RECQL, CXCR4, ADAM17, PPAT, PDE4B, PDE4C, AC008397.2, PDE4D, PTGDR, GPR17, KEAP1, PDE3A, IL11RA, TXNRD1, CA13, CSF3R, VKORC1, HRH4, NOD2, GPR35, IL23A, TNFSF13B, CA5B, HRH3, ACE2, TLR4, PSMD11, CDC7, PSMD14, STK25, TNFRSF10B, PSMA7, PDE8A, CTSV, NCOR1, ULK1, IDH1, TNFSF13, CHEK2, PLAT, ADA, IL1A, TTR, AFP, CXCL10, TFRC, APOB, TK1, CD74, APP, ALDH2, IL4, MPO, ITGB1, CEACAM5, NPM1, ITGAV, HI-0, HSP90AA1, HSP90AB1, ITGA5, VIM, GSTP1, CSF1, PARP1, CALM1, BCL2, SPP1, HSPA8, TOP1, ADH5, CCL2, EEF2, PLA2G2A, AKR1B1, FOLR1, CD19, PHKG2, MUC1, CD44, EPCAM, PRKCA, PRKACA, TNNI3, DDC, IL10, PRKACG, PRKACB, RPS6KB1, RRM1, PSMA2, PSMA3, PSMA4, PSMB9, PSMA5, PSMB5, BDKRB2, CPS1, RRM2, KIF5B, GUCY1A2, ABCC1, SOAT1, BSG, PSMC2, SNCA, GGCX, IL6ST, HTT, GLP1R, GPD2, PSMC4, BDKRB1, PSMD8, IDH2, PSMB3, PSEN1, GSK3A, PSMD7, KIF11, NR1H2, GFER, HDAC4, PSMA6, PSMC1, PSMC5, HBA2, HBA1, PRKDC, NFKB2, KMT2A, PTK2, PRKCZ, PRKCD, BCL2L1, MCL1, MFG8, PAK2, PSMD2, MAP3K1, HDAC1, IL18, PSMD6, PDK1, RPS6KA1, SHH, MYLK, ADRM1, CCDC6, BCL2A1, TMEM97, RRM2B, DPP9, MAPKAPK5, ABHD12, PCSK9, TRPV1, HDAC7, MUC16, HDAC2, BCL2L2, BCL2L2-PABPN1, PSMD1, GPA33, TSG101, IL22, RTN4, RPS6KB2, STK17A, PSMD13, NCOR2, STK24</i></p>	
--	--	--

439

440

441

**Supplemental Table S14. Functional enrichment analysis of 190 up-DEGs associated with severe COVID-19 based on the Reactome database**

Description	Size	Ratio	P Value	FDR
Immune System	1997	2.56	1.65E-14	2.86E-11
Innate Immune System	1053	3.24	1.79E-12	1.55E-09
Neutrophil degranulation	479	4.07	3.39E-09	1.95E-06
Negative regulators of DDX58/IFIH1 signaling	34	16.71	1.49E-07	6.45E-05
Cellular responses to external stimuli	503	3.23	3.15E-06	1.09E-03
DDX58/IFIH1-mediated induction of interferon-alpha/beta	78	8.33	4.86E-06	1.40E-03
Interleukin-4 and Interleukin-13 signaling	108	6.77	6.92E-06	1.71E-03
Adaptive Immune System	756	2.58	1.45E-05	3.13E-03
Interferon alpha/beta signaling	69	8.24	2.09E-05	4.02E-03
Cellular responses to stress	426	3.05	6.63E-05	1.15E-02
Regulation of TLR by endogenous ligand	19	17.09	7.38E-05	1.16E-02
Cytokine Signaling in Immune system	688	2.48	9.46E-05	1.36E-02
Interferon gamma signaling	92	6.18	1.34E-04	1.79E-02

Interferon Signaling	197	4.12	1.56E-04	1.93E-02
Class I MHC mediated antigen processing & presentation	371	3.06	1.86E-04	2.14E-02
Antigen processing-Cross presentation	99	5.74	2.13E-04	2.30E-02
IRF3-mediated induction of type I IFN	13	18.74	4.77E-04	4.85E-02

442

443

444

**Supplemental Table S15. Disease-based enrichment analysis of 190 up-DEGs associated with severe COVID-19 among *CCR1*+ *CD16*+monocytes based on the GLAD4U database.**

Disease terms	Size	Expect	Enrichment Ratio	P Value	FDR
Infection	643	5.19	5.40	2.90E-13	7.88E-10
Virus Diseases	580	4.68	5.56	1.17E-12	1.59E-09
Inflammation	565	4.56	5.48	4.42E-12	4.01E-09
Hepatitis	253	2.04	7.84	2.45E-10	1.67E-07
Immune System Diseases	806	6.50	3.84	7.35E-09	4.00E-06
Necrosis	371	2.99	5.35	5.79E-08	2.62E-05
Hyperoxia	33	0.27	22.54	2.32E-07	9.03E-05
HIV	862	6.95	3.31	4.60E-07	1.37E-04
Respiratory Tract Infections	281	2.27	5.73	4.85E-07	1.37E-04
virological response	282	2.28	5.71	5.05E-07	1.37E-04
Sexually Transmitted Diseases	496	4.00	4.25	5.76E-07	1.42E-04
Encephalitis, Viral	66	0.53	13.15	1.02E-06	2.31E-04
Bacterial Infections	260	2.10	5.72	1.39E-06	2.91E-04
Retroviridae Infections	494	3.99	4.01	2.62E-06	4.87E-04
HIV Infections	495	3.99	4.01	2.69E-06	4.87E-04
Lentivirus Infections	498	4.02	3.98	2.90E-06	4.93E-04
Hepatitis B	190	1.53	6.52	3.39E-06	5.42E-04
Mouth Diseases	246	1.98	5.54	5.25E-06	7.93E-04
Reperfusion Injury	86	0.69	10.09	6.15E-06	8.80E-04
Encephalitis	89	0.72	9.75	7.73E-06	1.05E-03
West Nile Fever	35	0.28	17.71	8.58E-06	1.11E-03

Immunologic Deficiency Syndromes	500	4.03	3.72	1.36E-05	1.66E-03
Rhinitis	135	1.09	7.35	1.40E-05	1.66E-03
Tumor Virus Infections	186	1.50	6.00	2.07E-05	2.35E-03
Psoriasis	243	1.96	5.10	2.90E-05	3.16E-03
Autoimmune Diseases	546	4.40	3.41	3.76E-05	3.93E-03
Arthritis, Reactive	78	0.63	9.54	4.00E-05	3.99E-03
Skin and Connective Tissue Diseases	617	4.98	3.21	4.11E-05	3.99E-03
Skin Diseases, Viral	85	0.69	8.75	6.50E-05	6.07E-03
Stress	643	5.19	3.08	6.70E-05	6.07E-03
Connective Tissue Diseases	392	3.16	3.79	8.40E-05	7.32E-03
Hepatitis, Chronic	174	1.40	5.70	8.61E-05	7.32E-03
Liver Neoplasms	396	3.19	3.76	9.25E-05	7.61E-03
Periodontitis	91	0.73	8.17	9.52E-05	7.61E-03
Respiratory Syncytial Virus Infections	229	1.85	4.87	1.04E-04	8.09E-03
Gram-Positive Bacterial Infections	181	1.46	5.48	1.13E-04	8.56E-03
Periodontal Diseases	96	0.77	7.75	1.28E-04	9.41E-03
Dermatitis, Atopic	140	1.13	6.20	1.43E-04	1.02E-02
Dermatomyositis	34	0.27	14.58	1.57E-04	1.09E-02
Hepatitis C	195	1.57	5.09	1.89E-04	1.27E-02
Lipidoses	67	0.54	9.25	2.07E-04	1.31E-02
Pneumonia	109	0.88	6.82	2.57E-04	1.45E-02
Adenocarcinoma	522	4.21	3.09	3.27E-04	1.81E-02
Chondrodysplasia Punctata	83	0.67	7.47	5.62E-04	2.88E-02
Lupus erythematosus	294	2.37	3.79	6.56E-04	3.08E-02
Leukemia	565	4.56	2.85	6.87E-04	3.11E-02
Pharyngeal Neoplasms	137	1.11	5.43	8.66E-04	3.62E-02



Frostbite	6	0.05	41.32	9.50E-04	3.64E-02
Actinomycetales Infections	145	1.17	5.13	1.16E-03	4.00E-02
Measles	62	0.50	8.00	1.58E-03	4.73E-02

445

446

447

**Supplemental Table S16. 190 up-DEGs associated with severe COVID-19 among *CCR1+* *CD16+* monocytes matched in druggable gene categories based on the DGIdb resource**

<b>Druggable Gene Category</b>	<b>Matching Gene Count</b>	<b>Matching Gene(s)</b>
Druggable genome	65	<i>AHR, APOBEC3A, ASGR1, C1QB, CD14, CD163, CD300E, CD36, CD53, CD63, CD84, CD99, CDKN1A, CTSA, CTSD, CTSL, CXCL8, CYP1B1, FKBP5, FOLR3, FPR1, FPR2, GLUL, HBEGF, HIF1A, HRH2, HSPA5, ICAM1, IFITM1, IGFBP7, IL4R, ISG15, LAIR1, LDHA, LGALS3BP, MGST1, NAMPT, PARP9, PGD, PIM1, PIM3, PLBD1, PLSCR1, PPIF, PSMA1, P XK, RNASE2, S100A12, S100A8, S100A9, SELL, SERPING1, SGK1, SIGLEC1, SLC12A7, SLC25A37, SLC2A3, SMPDL3A, TCN2, TNFAIP2, TNFSF10, TXN, TXNRD2, UPPI, VCAN</i>
Enzyme	35	<i>AHR, APOBEC3A, ATG12, BLVRB, CTSA, CTSD, CTSL, CYP1B1, DYNLL1, GLRX, GLUL, GM2A, HIF1A, HSPA5, IFIH1, ISG15, KRTCAP2, NCF1, PARP9, PGD, PIM1, PIM3, P XK, S100A8, S100A9, SGK1, SMPDL3A, SUMO3, SUPT5H, TNFAIP3, UBE2B, UBE2K, UBE2L3, UBE2V2, UPPI</i>
Kinase	21	<i>CCNLI, CD163, CD300E, CD63, CDKN1A, GADD45GIP1, HRH2, IFIH1, IRF3, MPLKIP, PIM1, PIM3, P XK, RGCC, S100A12, S100A8, S100A9, SGK1, SOCS3, STING1, TNFAIP3</i>

Clinically actionable	18	<i>BCL3, CAMTA1, CD36, CDKN1A, CYP11B1, ETV6, HIF1A, H2BC12, IRF2, MAML2, NOP10, PER1, PIM1, PRCC, SGK1, SOCS3, STING1, TNFAIP3</i>
Transcription factor	14	<i>AHR, ATF3, CAMTA1, CEBPB, CEBPD, ETV6, HIF1A, ID1, IFI16, IRF2, IRF3, PER1, SCAND1, SGK1</i>
Cell surface	8	<i>C1QB, CD36, CD53, CD63, HBEGF, HSPA5, ICAM1, VAMP5</i>
Transporter	8	<i>CD36, EMB, HIF1A, HSPA5, SGK1, SLC12A7, SLC25A37, SLC2A3</i>
Transcription factor binding	7	<i>AHR, BCL3, HIF1A, ID1, IFI16, PIM1, STING1</i>
Drug resistance	6	<i>CDKN1A, ICAM1, LDHA, MGST1, SGK1, UBE2B</i>
External side of plasma membrane	6	<i>CD14, CD163, CD36, FLOT1, ICAM1, SLC12A7</i>
Protease	5	<i>CTSA, CTSD, CTSL, PSMA1, TNFAIP3</i>
Protease inhibitor	4	<i>APLP2, HSPA5, NAIP, SERPING1</i>
Serine threonine kinase	4	<i>PIM1, PIM3, PXX, SGK1</i>
G protein coupled receptor	3	<i>FPRI, FPR2, HRH2</i>
Nuclear hormone receptor	3	<i>AHR, GADD45GIP1, PER1</i>

**Supplemental Table S17. Highly-expressed inflammatory and cytokine genes among ABO+ megakaryocytes**

Gene name	T score	Fold change	P value	FDR
<i>ADORA2B</i>	2.80	2.27	5.29E-03	2.227E-02
<i>ADRM1</i>	3.02	1.66	2.72E-03	1.301E-02
<i>AHR</i>	2.52	2.25	1.22E-02	4.349E-02
<i>GNA15</i>	3.49	1.82	5.35E-04	3.461E-03
<i>IRAK2</i>	3.20	2.85	1.48E-03	7.919E-03
<i>KCNA3</i>	3.29	1.89	1.10E-03	6.179E-03

<i>PDGFA</i>	4.26	1.71	2.53E-05	2.666E-04
<i>PTGIR</i>	4.05	1.56	6.18E-05	5.671E-04
<i>SPHK1</i>	3.71	1.57	2.36E-04	1.745E-03
<i>BMP6</i>	2.90	2.44	3.96E-03	1.766E-02
<i>TNFSF4</i>	4.81	2.67	2.18E-06	3.138E-05

451  
452  
453

**Supplemental Table S18. Pathway enrichment analysis of 424 highly-expressed genes among *ABO*+ megakaryocytes.**

Pathway name	Gene size	Enrichment ratio	P Value	FDR
Systemic lupus erythematosus	133	4.79	4.55E-07	1.48E-04
Alcoholism	180	4.01	9.82E-07	1.60E-04
Platelet activation	123	3.80	1.42E-04	1.55E-02
SNARE interactions in vesicular transport	34	6.24	1.10E-03	8.94E-02
Endocytosis	244	2.43	1.80E-03	1.17E-01
Viral carcinogenesis	201	2.53	2.74E-03	1.28E-01
VEGF signaling pathway	59	4.32	2.52E-03	1.28E-01
Necroptosis	162	2.62	4.83E-03	1.61E-01
Mitophagy	65	3.92	4.11E-03	1.61E-01
Chemokine signaling pathway	189	2.47	4.95E-03	1.61E-01
Transcriptional misregulation in cancer	186	2.28	1.23E-02	3.65E-01
Axon guidance	175	2.18	2.23E-02	6.05E-01
Bacterial invasion of epithelial cells	74	2.87	2.99E-02	6.51E-01
Regulation of actin cytoskeleton	213	1.99	2.88E-02	6.51E-01
Adherens junction	72	2.95	2.70E-02	6.51E-01
Human cytomegalovirus infection	225	1.89	3.97E-02	8.08E-01
Proteoglycans in cancer	201	1.90	4.77E-02	8.64E-01
Tight junction	170	2.00	4.73E-02	8.64E-01

454  
455  
456

**Supplemental Table S19. Disease-term enrichment analysis of 35 up-DEGs associated with severe COVID-19 among *ABO*+ megakaryocytes based on the GLAD4U database**

Term ID	Disease-terms	Size	Expect	Enrichment Ratio	P Value
PA443490	Bernard-Soulier Syndrome	9	0.01	140.31	8.69E-05

PA445644	Shock	367	0.58	8.60	2.59E-04
PA443842	Death	417	0.66	7.57	4.65E-04
PA445846	Thrombocytopenia	96	0.15	19.73	4.67E-04
PA443382	Anoxia	251	0.40	10.06	6.36E-04
PA445457	Pterygium	25	0.04	50.51	7.13E-04
PA165108957	Venous ulcer of leg	26	0.04	48.57	7.71E-04
PA166048906	Blood Platelet Disorders	118	0.19	16.05	8.51E-04
PA444668	Keratitis	31	0.05	40.74	1.10E-03
PA166129556	disease activity score 28 joint in rheumatoid arthritis	31	0.05	40.74	1.10E-03
PA443429	Arteritis	34	0.05	37.14	1.32E-03
PA443882	Dermatomyositis	34	0.05	37.14	1.32E-03
PA445850	Thrombosis	141	0.22	13.43	1.42E-03
PA166123766	platelet aggregation	153	0.24	12.38	1.80E-03
PA446220	Abdominal Pain	43	0.07	29.37	2.11E-03
PA445793	Synovitis	47	0.07	26.87	2.51E-03
PA443433	Arthritis, Juvenile Rheumatoid	48	0.08	26.31	2.62E-03
PA445051	Necrosis	371	0.59	6.81	2.68E-03
PA446477	Polymyositis	49	0.08	25.77	2.73E-03
PA166048887	Irritable Bowel Syndrome	50	0.08	25.26	2.84E-03
PA445752	Stress	643	1.02	4.91	3.17E-03
PA445593	Sarcoidosis	56	0.09	22.55	3.55E-03
PA444034	Endocarditis	67	0.11	18.85	5.04E-03
PA443829	Cystic Fibrosis	223	0.35	8.49	5.20E-03
PA445044	Nasal Polyps	75	0.12	16.84	6.27E-03
PA444035	Endocarditis, Bacterial	76	0.12	16.62	6.44E-03
PA445512	Arthritis, Reactive	78	0.12	16.19	6.77E-03
PA446020	Varicose Veins	79	0.13	15.99	6.94E-03

PA165108622	Drug interaction with drug	494	0.78	5.11	7.38E-03
PA165374639	suicide	83	0.13	15.22	7.63E-03
PA446303	Tooth Loss	84	0.13	15.03	7.81E-03
PA444942	Methemoglobinemia	5	0.01	126.28	7.89E-03
PA447296	nondiabetic proteinuric nephropathy	5	0.01	126.28	7.89E-03
PA443474	Bacterial Infections	260	0.41	7.29	7.93E-03
PA445672	Sinusitis	89	0.14	14.19	8.73E-03
PA443690	Charcot-Marie-Tooth Disease	95	0.15	13.29	9.90E-03
PA445382	Polyps	95	0.15	13.29	9.90E-03
PA445296	Periodontal Diseases	96	0.15	13.15	1.01E-02
PA447230	HIV	862	1.37	3.66	1.08E-02
PA165108641	Acatalasia	7	0.01	90.20	1.10E-02
PA165108334	Ulnar neuropathy	8	0.01	78.93	1.26E-02
PA446833	Pouchitis	8	0.01	78.93	1.26E-02
PA445355	Pneumonia	109	0.17	11.59	1.29E-02
PA446540	Cytomegalovirus Retinitis	9	0.01	70.16	1.42E-02
PA447149	Chills	9	0.01	70.16	1.42E-02
PA444231	Fructose Intolerance	10	0.02	63.14	1.57E-02
PA443820	Cryptococcosis	11	0.02	57.40	1.73E-02

457

458

459

**Supplemental Table S20. 35 up-DEGs significantly associated with severe COVID-19 among ABO+ megakaryocytes matched in druggable gene categories**

<b>Druggable Gene Category</b>	<b>Matching Gene Count</b>	<b>Matching Gene(s)</b>
Druggable genome	11	<i>ACPI, CFLAR, CYB5R3, FKBP8, HSPB1, MPIG6B, P2RX1, S100A8, S100A9, SMOX, TUBB1</i>
Enzyme	9	<i>ACPI, ATP6V1E1, CYB5R3, ENO1, HK1, S100A8, S100A9, SMOX, SUPT4H1</i>
Kinase	5	<i>HCST, HK1, S100A8, S100A9, SKP1</i>

Transporter	4	<i>ATF4, ATP6V1E1, SEC14L1, SLC44A2</i>
Cell surface	2	<i>ENO1, HCST</i>
Clinically actionable	1	<i>MYH9</i>
Drug resistance	1	<i>CFLAR</i>
External side of plasma membrane	1	<i>P2RX1</i>
Ion channel	1	<i>P2RX1</i>
Protease	1	<i>CFLAR</i>
Protein phosphatase	1	<i>ACPI</i>
Transcription factor	1	<i>ATF4</i>

460

461

462

**Supplemental Table S21. Pathway enrichment analysis of 158 highly-expressed genes among CXCR6+ memory CD8+T cells.**

Pathway name	Size	Enrichment Ratio	P Value	FDR
Cytokine-cytokine receptor interaction	294	5.65	1.24E-08	4.04E-06
Inflammatory bowel disease (IBD)	65	9.58	3.43E-05	5.58E-03
NF-kappa B signaling pathway	95	5.46	2.14E-03	2.32E-01
Toxoplasmosis	113	4.59	4.54E-03	2.85E-01
Necroptosis	162	3.84	4.55E-03	2.85E-01
Allograft rejection	38	8.19	5.69E-03	2.85E-01
Pyruvate metabolism	39	7.98	6.12E-03	2.85E-01
ABC transporters	44	7.07	8.57E-03	3.49E-01
Apoptosis	136	3.81	9.81E-03	3.55E-01
Intestinal immune network for IgA production	49	6.35	1.15E-02	3.76E-01
Autoimmune thyroid disease	53	5.87	1.43E-02	4.23E-01
Chagas disease (American trypanosomiasis)	102	4.07	1.66E-02	4.51E-01
Human cytomegalovirus infection	225	2.77	2.09E-02	5.25E-01
Kaposi sarcoma-associated herpesvirus infection	186	2.79	3.32E-02	6.83E-01
Citrate cycle (TCA cycle)	30	6.92	3.35E-02	6.83E-01

Chemokine signaling pathway	189	2.74	3.52E-02	6.83E-01
Circadian rhythm	31	6.69	3.56E-02	6.83E-01
Measles	132	3.14	3.81E-02	6.85E-01
Apoptosis	33	6.29	3.99E-02	6.85E-01
Phenylalanine, tyrosine and tryptophan biosynthesis	5	20.75	4.73E-02	7.71E-01

**Supplemental Table S22. GO-terms enrichment analysis of 108 up-DEGs associated with COVID-19 among *CXCR6*+ memory CD8+T cells.**

GO-terms	Size	Enrichment ratio	P Value	FDR
Immune response-activating cell surface receptor signaling pathway	300	6.79	6.30E-07	2.83E-03
Positive regulation of immune system process	979	3.59	9.22E-07	2.83E-03
Immune response-activating signal transduction	454	5.30	9.34E-07	2.83E-03
Immune response-regulating cell surface receptor signaling pathway	330	6.17	1.60E-06	3.54E-03
Immune response-regulating signaling pathway	485	4.96	1.95E-06	3.54E-03
Post-translational protein modification	360	5.66	3.71E-06	4.83E-03
Regulation of immune system process	1400	2.91	3.72E-06	4.83E-03
Positive regulation of immune response	706	3.93	5.21E-06	5.63E-03
Activation of immune response	534	4.51	5.58E-06	5.63E-03
Leukocyte differentiation	496	4.48	1.41E-05	1.28E-02
Hemopoiesis	791	3.51	2.01E-05	1.66E-02
Hematopoietic or lymphoid organ development	833	3.33	3.67E-05	2.78E-02
Regulation of hemopoiesis	389	4.76	4.64E-05	3.25E-02
Immune response-regulating cell surface receptor signaling pathway involved in phagocytosis	76	12.18	5.61E-05	3.28E-02
Fc-gamma receptor signaling pathway involved in phagocytosis	76	12.18	5.61E-05	3.28E-02
Immune response	1919	2.32	5.76E-05	3.28E-02
Antigen receptor-mediated signaling pathway	184	7.04	6.16E-05	3.29E-02
Fc-gamma receptor signaling pathway	79	11.72	6.75E-05	3.32E-02
Immune system development	881	3.15	6.94E-05	3.32E-02
Fc receptor mediated stimulatory signaling pathway	81	11.43	7.61E-05	3.46E-02

Regulation of leukocyte differentiation	263	5.63	8.77E-05	3.80E-02
Regulation of immune response	909	3.06	9.86E-05	4.07E-02

466

467 **References**

- 468 1. M. Ghousaini *et al.*, Open Targets Genetics: systematic identification of trait-associated  
469 genes using large-scale genetics and functional genomics. *Nucleic Acids Res* **49**, D1311-  
470 d1320 (2021).
- 471 2. Y. Ma *et al.*, Integrative Genomics Analysis Reveals a 21q22.11 Locus Contributing Risk  
472 to COVID-19. *Hum Mol Genet*, (2021).
- 473 3. E. Pairo-Castineira *et al.*, Genetic mechanisms of critical illness in COVID-19. *Nature*  
474 **591**, 92-98 (2021).
- 475 4. C. A. de Leeuw, J. M. Mooij, T. Heskes, D. Posthuma, MAGMA: generalized gene-set  
476 analysis of GWAS data. *PLoS Comput Biol* **11**, e1004219 (2015).
- 477 5. A. Auton *et al.*, A global reference for human genetic variation. *Nature* **526**, 68-74 (2015).  
478